GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Intrinsic Value: Projected FCF

Accelerated Pharma (Accelerated Pharma) Intrinsic Value: Projected FCF : $0.00 (As of May. 17, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-17), Accelerated Pharma's Intrinsic Value: Projected FCF is $0.00. The stock price of Accelerated Pharma is $0.00. Therefore, Accelerated Pharma's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Accelerated Pharma's Intrinsic Value: Projected FCF or its related term are showing as below:

ACCP's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.59
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Accelerated Pharma Intrinsic Value: Projected FCF Historical Data

The historical data trend for Accelerated Pharma's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Intrinsic Value: Projected FCF Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Intrinsic Value: Projected FCF
- - -

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Intrinsic Value: Projected FCF Get a 7-Day Free Trial - - - - -

Competitive Comparison of Accelerated Pharma's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerated Pharma's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Price-to-Projected-FCF falls into.



Accelerated Pharma Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Accelerated Pharma  (NAS:ACCP) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Accelerated Pharma's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.00/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerated Pharma Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerated Pharma (Accelerated Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines